Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Third-generation TKI”

39 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 39 results

Not applicableLooking for participantsNCT06304441
What this trial is testing

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Who this might be right for
Leptomeningeal Metastasis
Guangzhou Medical University 100
Not applicableUnknownNCT04768491
What this trial is testing

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Who this might be right for
EGFR Activating MutationNSCLC Stage IVNSCLC Stage IIIB+1 more
Peking Union Medical College 82
Testing effectiveness (Phase 2)WithdrawnNCT05604755
What this trial is testing

Prophylactic HQP1351 Therapy Post-transplants on Leukemia After Allo-HSCT

Who this might be right for
Prophylactic HQP1351 TherapyThird Generation TKI
xuna
Not applicableUnknownNCT05663177
What this trial is testing

Almonertinib Plus Metronomic Oral Vinorelbine

Who this might be right for
EGFRNSCLCThird-generation TKI
Fujian Cancer Hospital 40
Very early researchNot Yet RecruitingNCT07498595
What this trial is testing

TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

Who this might be right for
EGFR-TKI-resistant Non-Small Cell Lung Cancer
Tianjin Medical University General Hospital 50
Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07193160
What this trial is testing

Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)
Fudan University 45
Not applicableLooking for participantsNCT07398599
What this trial is testing

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Who this might be right for
Leptomeningeal MetastasisLung Neoplasms, Non-Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University 30
Not applicableUnknownNCT05497076
What this trial is testing

The Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Who this might be right for
Non-small Cell Lung Cancer Confirmed by Histopathology or CytologyThe TNM (8th) Phase is IVWith EGFR Mutations+4 more
Fujian Cancer Hospital 9
Large-scale testing (Phase 3)WithdrawnNCT06093503
What this trial is testing

Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein

Who this might be right for
Non-Small Cell Lung Cancer
AbbVie
Not applicableLooking for participantsNCT05598528
What this trial is testing

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)

Who this might be right for
Lung Cancer, Non-small CellEGFR Gene MutationEGFR-TKI Resistant Mutation+2 more
Second Xiangya Hospital of Central South University 210
Early research (Phase 1)Active Not RecruitingNCT04077463
What this trial is testing

Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC 701
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479
What this trial is testing

Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis
Zhejiang Cancer Hospital 45
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07789444
What this trial is testing

Sacituzumab Tirumotecan（Sac-TMT） and Brain Radotherapy for EGFR+ NSCLC With Brain Mets

Who this might be right for
Non-Small Cell Lung CancerBrain Metastases From Non-small Cell Lung Cancer (NSCLC)EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Xiaorong Dong 53
Not applicableStudy completedNCT06613633
What this trial is testing

Third-generation EGFR-TKI Treatment in Metastatic EGFR-mutant NSCLC

Who this might be right for
Third-generation TKINSCLC (Advanced Non-small Cell Lung Cancer)
Fudan University 4,000
Early research (Phase 1)Not Yet RecruitingNCT07798921
What this trial is testing

JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure

Who this might be right for
CarcinomaNon-Small-Cell Lung
Yonsei University 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07780578
What this trial is testing

The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
Fudan University 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06818955
What this trial is testing

Orlistat Overcoming Third-generation EGFR-TKI Resistance

Who this might be right for
Lung AdenocarcinomaOsimertinib
Ping Peng 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07197008
What this trial is testing

Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis

Who this might be right for
Lung Cancer
Li-kun Chen 50
Early research (Phase 1)Not Yet RecruitingNCT06585059
What this trial is testing

Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers

Who this might be right for
Advanced Non-small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. 20
Next Page